BEN's AI Breakthrough to Reshape Pharma-Patient Engagement

JACKSON, WY – December 29, 2025 – Brand Engagement Network (NYSE: BNAI), a specialist in secure generative AI, today announced a pivotal agreement that marks its deepest foray yet into the highly regulated pharmaceutical industry. The company has finalized a deal with a leading global advertising agency to develop a proprietary AI engagement solution for a top-10 global pharmaceutical company, aimed at transforming how information about an established prescription drug is communicated to patients and providers.

While the identities of the pharmaceutical giant and the advertising agency remain confidential pending a formal product launch, the deal provides a significant validation of BEN's technology. The company expects to recognize $250,000 in development revenue in the fourth quarter of 2025, with a more lucrative recurring monthly licensing fee structure anticipated to begin in the first quarter of 2026. This move signals a strategic shift from one-time development fees to a more stable, subscription-based revenue model, a development closely watched by investors.

A New Frontier in Patient Communication

The core of the agreement is the creation of a custom "AI engagement communication method." This solution aims to leverage BEN's expertise in conversational AI, including its human-like avatars, to create a secure, multi-modal platform for interaction. The goal is to move beyond static websites and call centers, offering a dynamic and personalized resource for patients and healthcare professionals.

In practice, such a system could serve multiple functions. For patients, it could act as a sophisticated virtual assistant, providing on-demand, accurate information about dosage, potential side effects, and adherence schedules. By offering personalized reminders and answering questions in natural language, the AI could significantly improve patient comprehension and compliance, critical factors in treatment success. BEN's multi-modal capabilities—incorporating text, voice, and vision—could allow for more intuitive and accessible interactions than traditional text-only chatbots.

For healthcare providers, the AI tool could streamline access to the latest clinical trial data, drug efficacy information, and prescribing guidelines. This would ensure that busy professionals have a reliable and efficient channel for obtaining crucial information, freeing up time for direct patient care. The platform is being designed to deliver what BEN calls "trusted, secured, and efficient AI," a key requirement for pharma manufacturers who must ensure all communications are medically precise and compliant.

Navigating a Highly Regulated Landscape

Deploying AI within pharmaceutical marketing and communication is fraught with regulatory challenges, making this agreement a notable achievement. The industry is governed by stringent rules from bodies like the U.S. Food and Drug Administration (FDA) to ensure patient safety and prevent the dissemination of misleading information.

Any AI system communicating about prescription drugs must be meticulously designed to provide information that is strictly consistent with the approved drug labeling. A primary concern is preventing "off-label promotion," where a drug is marketed for uses not approved by the FDA. The AI's algorithms must have robust guardrails to avoid this, alongside mechanisms for identifying and reporting adverse events mentioned by users.

Furthermore, patient privacy is paramount. Handling sensitive personal health information (PHI) requires strict adherence to privacy laws like the Health Insurance Portability and Accountability Act (HIPAA) in the United States. BEN's strategic emphasis on providing "safe and secure generative AI" is its main selling proposition in this high-stakes environment. This focus suggests a platform architected from the ground up with data encryption, access controls, and compliance at its core, a feature that was likely critical in securing the confidence of its top-tier client.

Strategic Validation and Financial Implications

For Brand Engagement Network, this deal is more than just a new contract; it's a powerful strategic validation. Securing a partnership involving a top-10 pharmaceutical company and a major global ad agency signals that BEN's technology is perceived as mature and secure enough for one of the world's most demanding industries.

The financial structure of the deal is particularly significant. The initial $250,000 in development revenue provides an immediate boost to the company's Q4 2025 results. However, the true long-term value lies in the anticipated recurring license fees starting in 2026. This subscription-based model is highly favored by investors as it creates a predictable and scalable revenue stream, moving the company toward more stable financial footing.

This stability is crucial for BEN, which has faced profitability challenges. Recent data has shown negative operating margins and modest sales figures. In response, the company has been actively working to strengthen its balance sheet, successfully cutting liabilities by approximately $2.5 million in the fourth quarter through strategic debt conversions. This new, high-profile agreement, combined with disciplined financial management, could mark a turning point for the company, demonstrating a clear path to growth and validating its focus on high-value enterprise clients.

Building a Global Healthcare AI Strategy

This landmark agreement does not exist in a vacuum. It is the latest and most significant step in BEN's broader strategy to establish itself as a key player in the global healthcare AI market. The company has been methodically building its presence in the sector, both domestically and abroad.

BEN's expansion into Latin America is a key pillar of this strategy. Through an exclusive licensing partnership, the company is driving the adoption of its secure AI in Mexico and other regional markets. This includes the recent launch of Skye Salud, an AI-powered healthcare platform developed with partner Skye Inteligencia LATAM. Skye Salud is designed to modernize healthcare in Mexico, with an initial focus on managing chronic diseases like diabetes, which affects over 14 million adults in the country.

These international ventures, combined with the new agreement in the U.S. pharmaceutical market, paint a picture of a company with a cohesive global vision. By proving its capabilities in different regulatory environments and for different healthcare applications—from chronic disease management in emerging markets to sophisticated patient engagement for a global pharma leader—BEN is building a compelling case for its technology's versatility and security.